On September 5, Evernorth announced that it was applying its newly implemented policy on adalimumab biosimilars to the 2025 launch of ustekinumab biosimilars as well. Effective in early 2025, patients will be eligible to receive an interchangeable ustekinumab biosimilar without any cost sharing, through its Accredo specialty pharmacy. Evernorth stated in its press release that … Continue reading Evernorth Extends Its Biosimilar Strategy With Ustekinumab Launch: Zero Copays and Private Labeling